A harmonized and collaborative approach to the clinical testing, scale-up and distribution of candidate vaccines to prevent COVID-19 is essential, scientific leaders write in a perspective published today in Science.
As the COVID-19 pandemic continues, government, industry and academia have introduced a variety of vaccine candidates. The authors note that more than one effective vaccine approach likely will be required to successfully protect the global community from SARS-CoV-2, the virus that causes COVID-19. They describe a strategic approach to research and development that would generate essential data for multiple vaccine candidates in parallel.
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., Lawrence Corey, M.D., professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center in Seattle, and John R. Mascola, M.D., director of NIAID’s Vaccine Research Center are the co-authors of the commentary.
The perspective discusses diverse vaccine candidates and key considerations for development, including the characteristics of various vaccine platforms in terms of prior commercial experience, scalability, and the types of immune responses generated. It also emphasizes that no single vaccine or vaccine platform is likely to meet the global need, highlighting the need for a coordinated strategic approach to vaccine development.
The authors stress that researchers need to learn more about what constitutes a durable protective immune response against COVID-19. They review considerations for vaccine efficacy trials, explaining how trials for several candidate vaccines can be conducted in parallel to generate essential safety and efficacy data and accelerate the licensure and distribution of COVID-19 vaccines. The authors propose specific approaches to harmonizing the clinical testing of multiple vaccine products, including using common clinical trials designs, clinical endpoints, standardized immune assays and a common Data Safety and Monitoring Board.
The authors emphasize that developing COVID-19 vaccines will require unprecedented cooperation from governments, academic institutions, industry, and global philanthropic partners. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership spearheaded by NIH aims to facilitate such collaboration with discussions and collaborations on trial designs and data sharing.
Protecting the entire global community from COVID-19 through vaccination will require significant manufacturing capacity, according to the authors. They emphasize the need to fund the necessary biomanufacturing infrastructure and note possible hurdles in the eventual delivery of vaccines, including cost, distribution systems and cold chain requirements. The authors conclude that strategic collaboration among public and private sectors to effectively accelerate COVID-19 vaccine development is essential.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Mississippi health officials hopeful about COVID-19 vaccineon November 12, 2020 at 6:03 pm
Mississippi’s top health officials said Thursday that they are hopeful a coronavirus vaccine could become available for health care workers and first responders in the state as early as next month.
- Don't expect a coronavirus vaccine before December, experts cautionon November 12, 2020 at 5:35 pm
Pfizer released surprisingly positive data about its experimental coronavirus vaccine this week and may hope to apply for regulatory approval by the end of the month, but it will take several weeks ...
- Australian COVID-19 Vaccine Candidate Produces Antibody Response in Early Testson November 12, 2020 at 5:31 pm
SYDNEY (Reuters) - Early testing of a potential COVID-19 vaccine developed by an Australian university and CSL Ltd has shown it to be safe and produce an antibody response, Minister for Health Greg ...
- Moderna Closes in on Release of COVID-19 Vaccine Dataon November 12, 2020 at 4:17 pm
Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy. Moderna ...
- Pfizer in talks with Brazil to supply COVID-19 vaccine by early 2021on November 12, 2020 at 3:50 pm
The head of Pfizer Inc in Brazil said on Thursday the drugmaker is negotiating with the South American nation to supply its potential COVID-19 vaccine in the first quarter of 2021.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- California hits 1 million coronavirus cases; the second state to do so after Texason November 12, 2020 at 5:51 pm
California became the second state to surpass 1 million coronavirus cases on Thursday, according to data from Johns Hopkins University. The nation’s most populous state has now reported 1,000,631 ...
- Oil falls as COVID-19 spike stokes fuel demand fears; still set for big weekly gainon November 12, 2020 at 5:48 pm
Oil prices fell in early trade on Friday as a spike in the number of COVID-19 infections raised fears for the global economy and near-term fuel demand, but remained on track for a second straight ...
- Coronavirus live news: quarter of deaths in France linked to Covid as US tops 140,000 daily caseson November 12, 2020 at 5:39 pm
France’s lockdown extended by two weeks; German infection surge may be easing; Russia says its Sputnik-V vaccine is 92% effective ...
- Got miles? Hawaiian Airlines will let you redeem them for a coronavirus test kit.on November 12, 2020 at 5:31 pm
Hawaiian Airlines has found a novel way for you to put those frequent-flier miles to use. For a limited time, the carrier will allow customers to redeem them for a coronavirus test kit. “We remain ...
- Australian COVID-19 vaccine candidate produces antibody response in early testson November 12, 2020 at 5:17 pm
Early testing of a potential COVID-19 vaccine developed by an Australian university and CSL Ltd has shown it to be safe and produce an antibody response, Minister for Health Greg Hunt said on Friday.